Abstract Poster Wall
2022 Kidney Cancer Research Summit
Abstract 27
Evaluation of Growth Rates for Small Renal Masses in Elderly Patients Undergoing Active Surveillance
Ridwan Alam MD, MPH
Abstract 28
Optimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC): A prospective two arm phase II trial utilizing a novel RNA sequencing-based biomarker to assign treatments
Scott Haake MD
Abstract 32
VHL-mediated ubiquitination of the kinase Mps1 regulates the mitotic checkpoint in clear cell renal cell carcinoma
Mark Woodford PhD
Abstract 33
No Difference in Renal Function Outcomes for Patients with Oncocytoma Managed with Active Surveillance vs. Partial Nephrectomy
Spencer Bell MD
Abstract 34
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Scott Haake MD, PhD
Abstract 35
Role of Histology in Influencing Outcomes after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Pranjal Agrawal MD
Abstract 36
Cytoreductive Nephrectomy with Concomitant IVC Tumor Thrombectomy in Metastatic Renal Cell Carcinoma
Pranjal Agrawal MD
Abstract 42
Vascular endothelial profilin-1 Inhibition suppresses tumor progression in renal cancer
David Gau PhD
Abstract 44
Outcomes of patients with advanced variant histology renal cell carcinoma (RCC) treated with systemic therapy
Danielle Urman
Abstract 45
SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
Toni Choueiri MD
Abstract 48
Characterization of FH variants in their role in HLRCC-associated kidney cancer
Blake R Wilde PhD
Abstract 50
Pro-survival role of protein phosphatase-5 (PP5) in clear cell renal cell carcinoma through its post translational regulation
Rebecca A Sager MD, PhD
Abstract 51
Investigating germline susceptibility to renal cell carcinoma within the Canadian population
Kate I Glennon BSc
Abstract 54
Evaluating the clinical utility of Circulating Tumor Cells (CTC) profiling to predict selection of preferred therapeutic regimens in Newly Diagnosed or Pretreated Refractory Renal Cell Carcinoma (RCC)
Ulka Vaishampayan MD
Abstract 55
Biomarkers of Disease Burden and Treatment Response in Renal Medullary Carcinoma
Kyle Blum MD, MS
Abstract 57
Induction of mitochondrial metabolic activity and repression of antigen presentation underly progression of localized clear cell renal cell carcinoma
Behrouz Shamsaei PhD
Abstract 58
The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect in renal cancer
Jennifer Heritz
Abstract 61
Belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 treatment in patients with advanced renal cell carcinoma: the randomized, phase 3 LITESPARK-011 study
Daniel YC Heng MD, MPH
Abstract 65
Correlation of serum iron level and duration of response to ipilimumab and nivolumab in metastatic clear cell renal carcinoma (mccRCC)
James Brundage MS
Abstract 66
Clinical and Decision-Making Drivers of Renal Mass Biopsy for Clinical T1 Kidney Tumors
Kathryn Gessner MD, PhD
Abstract 67
Impact of Age on Functional Decline Following Radical Nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC)
Mimi Nguyen BS
Abstract 68
Comparison of Nephrectomy and Ablation for cT1b Renal Masses
Kerith Wang BA
Abstract 71
Clinical and genomic characteristics of patients with metastatic renal cell carcinoma who developed venous thromboembolism
Nicolas Sayegh MD
Abstract 73
Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression
Zoe Gan MD
Abstract 75
Maturation of overall survival (OS) in TIVO-3 with long-term follow-up
Brian Rini MD
Abstract 76
Gut microbiome metagenomic analysis identifies key functional pathways associated with sarcopenia development in patients with metastatic renal cell carcinoma
Zeynep Zengin MD
Abstract 79
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressively advanced stages of renal cell carcinoma, including brain metastases
David Schoenfeld MD, PhD
Abstract 81
Decisional conflict among patients newly diagnosed with clinical T1 renal masses
Amir Feinberg
Abstract 82
A Comparison of Radiographic and Morphometric Characteristics and Outcomes in T3A Pathologically Upstaged and Non-Upstaged Renal Cell Carcinoma
Saeed Ghassemzadeh
Abstract 84
Multiome single-cell genomics profiling identifies epigenetic, transcriptional, and cellular compositional shifts in clear cell renal cell carcinomas
Lucas Salas MD, PhD, MPH
Abstract 85
Pulmonary and cutaneous manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort
Brian Cortese BS
Abstract 86
Financial Burden of Kidney Cancer Care: CDC National Health Survey Analysis
Spencer Bell MD
Abstract 87
The Mutational Landscape of Resected Clear Cell Renal Cell Carcinoma with Cystic components
Laura Bukavina MD, MPH
Abstract 88
Renal mass manifestations of the Birt-Hoge-Dube syndrome in a large clinical cohort
David Ostrowski BS
Abstract 90
The role of exercise on the physical and mental health of kidney cancer patients and survivors
Khalid Alkhatib MD, MMSc
Abstract 92
Characteristics and Outcomes of T1a Renal Cell Carcinoma Presenting with Metastasis
Luke Wang MD
Posters: Trials in Progress
Abstract 39
Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
Kevin Zarrabi MD, MS
Abstract 41
TiNivo-2: A Phase 3 Study to Compare Tivozanib Plus Nivolumab to Tivozanib Monotherapy in Patients with RCC Who Have Progressed Following ≤2 Lines of Therapy Including an Immune Checkpoint Inhibitor
Toni Choueiri MD
Abstract 49
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety. PK, PD and clinical activity in patients with advanced ccRCC
Toni Choueiri MD
Abstract 60
Pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma: phase 3 LITESPARK-022 study
Toni Choueiri MD
Cabozantinib, Nivolumab and Ipilimumab (CaNI) for advanced Renal Cell Carcinoma with Variant Histology
Bradley A McGregor MD
ABSTRACT BOOK
Kidney Cancer Research Summit
October 6–7, 2022, Philadelphia, PA
Click the image above to download the Abstract Book.
Updated 10.4.22